Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verrica Pharmaceuticals Inc. (VRCA) SEC filings page on Stock Titan aggregates the company’s official submissions to the U.S. Securities and Exchange Commission, providing investors with direct access to its regulatory and financial disclosures. Verrica is a Nasdaq-listed dermatology therapeutics company focused on YCANTH® (VP-102) for molluscum contagiosum and common warts, and VP-315 for non-melanoma skin cancers, and its filings reflect the evolution of these programs and the company’s capital structure.
Through Verrica’s Forms 8-K, investors can track material events such as private placement financings of common stock and warrants, amendments to collaboration and license agreements with Torii Pharmaceutical Co. Ltd., reverse stock split actions, and notices and resolutions related to Nasdaq listing compliance. These current reports also incorporate press releases announcing quarterly financial results, where Verrica details product revenue from YCANTH, license and collaboration revenue from Torii, operating expenses, and net income or loss.
Filings related to collaboration amendments describe key economic terms, including milestone payments tied to YCANTH approvals in Japan, cost-sharing for the global Phase 3 program in common warts, and technology transfer and royalty arrangements for YCANTH applicator manufacturing. Capital markets filings outline the terms of private investments in public equity, including pre-funded warrants, Series C warrants, registration rights agreements and the intended use of proceeds, such as repayment of credit facilities and funding operations.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the most important elements of each filing, helping readers quickly understand how new agreements, financings, clinical milestones or listing actions may relate to Verrica’s dermatology and dermatologic oncology strategy. Users can review real-time updates from EDGAR, monitor unregistered sales of equity securities, and connect financial disclosures to the company’s ongoing development of YCANTH and VP-315.
Verrica Pharmaceuticals Inc. (VRCA) CEO, President and director reported a personal purchase of 94,311 investment units on 11/25/2025. Each unit includes one share of common stock and a Series C warrant to buy one fourth of a share, at a unit price of $4.2425.
The filing shows direct beneficial ownership of 182,593 common shares after the transaction, adjusted for a 1-for-10 reverse stock split effective July 24, 2025. The related Series C warrants cover 23,577 underlying common shares at an exercise price of $6.315 and are immediately exercisable, subject to a 9.99% beneficial ownership cap. Small additional holdings are reported indirectly through a child and family trusts.
Verrica Pharmaceuticals Inc. (VRCA) director and 10% owner Paul B. Manning reported large purchases of common stock and warrants. On 11/25/2025, he bought 1,375,380 investment units at $4.2425 per unit directly and 2,750,762 units indirectly through BKB Growth Investments, LLC. Each unit consists of one share of common stock and a Series C warrant to buy one fourth of a share at an exercise price of $6.315 per share, exercisable until 11/25/2030.
After these transactions, he beneficially owns millions of shares through direct holdings, BKB, family trusts and an investment entity, with some positions reported as disclaimed beneficial ownership. The Series C warrants are immediately exercisable but include a 49.99% beneficial ownership limitation, meaning they cannot be exercised to push his ownership above 49.99% of Verrica’s outstanding common stock after exercise. The reported share counts have been adjusted for Verrica’s 1-for-10 reverse stock split effective July 24, 2025.
Verrica Pharmaceuticals Inc. announced a private placement of equity and warrants with institutional and accredited investors. The company agreed to sell 6,499,826 shares of common stock, pre-funded warrants exercisable for 5,305,164 shares in lieu of some shares, and accompanying Series C warrants to purchase 2,951,241 shares. The purchase price is $4.24125 per share and accompanying Series C warrant, with pre-funded warrants priced at the same amount minus $0.0001, for anticipated gross proceeds of approximately $4.24115 million before fees.
The pre-funded warrants have a $0.0001 exercise price and no expiry until exercised, while the Series C warrants are immediately exercisable at $6.315 per share and expire five years after closing, subject to beneficial ownership limits generally capped at 19.99% or 9.99%. Verrica agreed to file resale registration statements for the shares and warrant shares and to use $35.0 million of net proceeds to settle and terminate its senior secured credit facility with OrbiMed. Caligan Partners LP will gain a Board designee and a Board observer right for as long as it retains specified pre-funded warrants.
Verrica Pharmaceuticals Inc. reported that it issued a press release announcing its financial results for the three and nine months ended September 30, 2025, and outlined plans for a conference call to discuss the results and business updates. The company furnished this earnings press release as Exhibit 99.1 to a Form 8-K dated November 14, 2025. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act, which means it is not subject to certain liability provisions or automatically incorporated into other SEC filings unless specifically referenced.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 9,235,571 shares of Verrica Pharmaceuticals Inc. (VRCA), representing 9.99% of the outstanding common stock. The filing states Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and exercises shared voting and dispositive power over the reported shares; Mr. Boyd, as managing member, is likewise reported with shared voting and dispositive power. The filing affirms the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Verrica Pharmaceuticals reported consolidated results for the quarter ended June 30, 2025 showing total revenue of $12.7 million, driven by $8.2 million of license and collaboration revenue and $4.5 million of net product sales of YCANTH (VP-102). The company recorded a small net income of $0.2 million for the quarter versus a large loss in the prior-year period, but a net loss of $9.5 million for the six months ended June 30, 2025.
Cash and cash equivalents declined to $15.4 million from $46.3 million at year-end, and the balance sheet shows total debt, net of discounts and issuance costs, of $37.3 million and a derivative liability of $1.8 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year unless additional financing is obtained; the Credit Agreement requires maintaining at least $10.0 million of liquidity and contains covenants that were partially waived for certain 2025 periods.
Key corporate actions include a 1-for-10 reverse stock split (effective July 24, 2025) and a June 27, 2025 amendment with Torii that accelerated an $8.0 million milestone (paid in July 2025) and sets cost-sharing and future royalty/transfer-price arrangements for a Phase 3 program for common warts.
Verrica Pharmaceuticals announced a press release reporting its financial results for the three- and six-month periods ended June 30, 2025 and disclosed details for a related conference call; that press release is furnished as Exhibit 99.1 to the current report. The filing also includes an interactive XBRL cover page file.
The company further disclosed that Nasdaq's Listing Qualifications Staff has determined the company has regained compliance with the bid price requirement under Nasdaq Listing Rule 5450(a)(1), indicating the company is currently meeting Nasdaq's listing standards for minimum bid price.
Verrica Pharmaceuticals Inc. (VRCA) filed an 8-K to disclose a Second Amendment to its March 2021 Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd.
- Up-front cash: Torii will pay Verrica an $8.0 million milestone tied to the ongoing global Phase 3 trial of YCANTH (VP-102) for common warts.
- Cost-sharing: The parties will continue to split trial expenses 50/50. Torii will advance the first $40.0 million of out-of-pocket costs; Verrica will subsequently reimburse Torii for half. If expenses exceed $40 million, Verrica will fund the overage (up to a stated cap) and Torii will reimburse 50% of that excess.
- Additional milestone: Torii agreed to a separate $10.0 million cash payment upon Japanese approval of YCANTH for molluscum contagiosum—paid in cash rather than as a trial-cost offset.
- Manufacturing rights: A technology-transfer program will allow Torii to manufacture the product. Until partial transfer is complete, Torii will buy commercial supply from Verrica at transfer pricing; thereafter Verrica will receive quarterly royalties in the high-single- to low-double-digit range.
- All other material terms of the original agreement remain unchanged.
The amendment improves Verrica’s near-term liquidity via non-dilutive funding, caps some development risk, and may accelerate commercial scale-up in Japan. A press release announcing the amendment (Exhibit 99.1) was issued on July 1, 2025.